Abstract Purpose of Review Clinical decisions for (neo) adjuvant treatment in early breast
cancer (eBC) have been based mostly on clinical factors over the last decades. We have …

Multi-gene assays have been widely used to predict the recurrence risk for hormone
receptor (HR)-positive breast cancer patients. However, these assays lack explanatory …

Introduction The prognostic capability of targeted sequencing of primary tumors in patients
with estrogen receptor‐positive, human epidermal growth factor receptor‐2‐negative early …

Background Both TP53 mutation and MYC amplification indicate poor outcomes in breast
cancer (BC), but the clinical values of concurrent TP53 and MYC alterations have not been …

Introduction HR+/HER2− breast cancer (BC) has a much lower pathological complete
response (pCR) rate to neoadjuvant chemotherapy (NAC). Therefore, to better stratify the …

Breast cancer is one of the most prevalent malignant tumors affecting women globally. It is a
heterogeneous disease characterized by mutations in several genes. Several gene panels …

Background Adjuvant chemotherapy is a major adjuvant treatment modality for hormonal
receptor (HR)-positive and HER2-negative early breast cancer, but only 2%-20% of patients …

Blood flow to the breast is typically supplied by the internal mammary, lateral thoracic, and
intercostal arteries. The three major breast lymphatic drainage routes are axillary …

Purpose The 21-gene recurrence score (RS) assay is currently used for predicting
chemotherapeutic benefits for hormone receptor-positive (HR+) early-stage breast cancer …